FilingReader Intelligence
Maccura Biotechnology revenue falls 16%, profit down 83%
July 31, 2025 at 10:20 AM UTC•By FilingReader AI
Maccura Biotechnology reported a 15.94% revenue decrease for the first half of 2025, with net profit attributable to shareholders down 83.12%. The decline was influenced by divested agency operations and increased asset impairment charges.
The company will inject 1.6 billion yuan into two wholly-owned subsidiaries through debt-to-equity conversions to optimize capital structure.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement regarding the provision for credit impairment and asset impairment lossesJuly 31, 2025 at 08:00 AM UTC
Announcement of resolutions from the fifth meeting of the sixth board of directorsJuly 31, 2025 at 08:00 AM UTC
2025 semi-annual report summaryJuly 31, 2025 at 08:00 AM UTC
Verification opinion of China Merchants Securities Co., Ltd. regarding Maccura Biotechnology Co., Ltd.'s capital increase in its wholly-owned subsidiary through debt-to-equity conversionJuly 31, 2025 at 08:00 AM UTC
Announcement regarding capital increase for wholly-owned subsidiary through debt-to-equity swapJuly 31, 2025 at 08:00 AM UTC
Special report on the deposit and use of raised funds for the first half of 2025July 31, 2025 at 08:00 AM UTC
Maike Biotech Co., Ltd. summary table of non-operating funds occupied and other related party fund transactions for the first half of 2025July 31, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Maccura Biotechnology publishes news
Free account required • Unsubscribe anytime